Development, Optimization and Use of Preclinical Behavioral Models to Maximize the Productivity of Drug Discovery for Alzheimer's Disease

Animal and Translational Models for CNS Drug Discovery

Volumn , Issue , 2008, Pages 93-157

  Lindner, Mark D ^a   McArthur, Robert A ^a   Deadwyler, Sam A ^b   Hampson, Robert E ^b   Tariot, Pierre N ^c  

^a McArthur and Associates GmbH   (Switzerland)

^b WAKE FOREST SCHOOL OF MEDICINE   (United States)

^c BANNER ALZHEIMER S INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84884894746     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-12-373861-5.00016-3     Document Type: Chapter

References (370)

1. D.P. Rice, H.M. Fillit, W. Max, D.S. Knopman, J.R. Lloyd and S. Duttagupta (2001) Prevalence, costs, and treatment of Alzheimer's disease and related dementia: A managed care perspective. Am J Manag Care 7(8), 809-818.
2. C. Barbui, A. Cipriani, C. Lintas, V. Bertele and S. Garattini (2007) CNS drugs approved by the centralised European procedure: true innovation or dangerous stagnation? Psychopharmacology (Berl) 190(2), 265-268.
3. M. Dickson and J.P. Gagnon (2004) The cost of new drug discovery and development. Discov Med 4(22), 172-179.
4. P. Tollman, G. Philippe, J. Altshuler, A. Flanagan and M. Steiner (2001) A revolution in R&D: How genomics and genetics are transforming the biopharmaceutical industry. Boston, MA: The Boston Consulting Group
5. J.A. DiMasi, R.W. Hansen and H.G. Grabowski (2003) The price of innovation: New estimates of drug development costs. J Health Econ 22(2), 151-185.
6. J. Gilbert, P. Henske and A. Singh (2003) Rebuilding big pharma's business model. In Vivo: The Business and Medicine Report 21(10), 1-10.
7. J.A. DiMasi (1995) Trends in drug development costs, times, and risks. Drug Inform J 29 375-384.
8. T. Kennedy (1997) Managing the drug discovery/development interface. Drug Discov Today 2 436-444.
9. J.A. DiMasi (2001) Risks in new drug development: Approval success rates for investigational drugs. Clin Pharmacol Ther 69(5), 297-307.
10. R.A. Prentis, Y. Lis and S.R. Walker (1988) Pharmaceutical innovation by the seven UK-owned pharmaceutical companies (1964–1985). Br J Clin Pharmacol 25(3), 387-396.
11. D. Schuster, C. Laggner and T. Langer (2005) Why drugs fail – A study on side effects in new chemical entities. Curr Pharm Des 11(27), 3545-3559.
12. C.G. Lyketsos, M. Steinberg, J.T. Tschanz, M.C. Norton, D.C. Steffens and J.C. Breitner (2000) Mental and behavioral disturbances in dementia: Findings from the Cache County Study on Memory in Aging. Am J Psychiatr 157(5), 708-714.
13. R.T. Bartus, R.L. Dean III., B. Beer and A.S. Lippa (1982 Jul 30) The cholinergic hypothesis of geriatric memory dysfunction. Science 217(4558), 408-414.
14. R.T. Bartus and D.F. Emerich (1999 Dec 15) Cholinergic markers in Alzheimer disease. JAMA 282(23), 2208-2209.
15. D.K. Lahiri and M.R. Farlow (2003) Review: Cholinesterase inhibitors have a modest effect on neuropsychiatric and functional outcomes in Alzheimer's disease. Evid Based Ment Health 6(3), 94.
16. E.R. Peskind, S.G. Potkin, N. Pomara, B.R. Ott, S.M. Graham, J.T. Olin, et al. (2006 Jul 21) Memantine treatment in mild to moderate Alzheimer's disease: A 24-week randomized, controlled trial. Am J Geriatr Psychiatr 14 704-715.
17. J. Hardy (2006) Alzheimer's disease: The amyloid cascade hypothesis: An update and reappraisal. J Alzheimers Dis 9(3 Suppl), 151-153.
18. J.A. Hardy and G.A. Higgins (1992 Apr 1) Alzheimer's disease: The amyloid cascade hypothesis. Science 256(5054), 184-185.
19. D.J. Selkoe, T. Yamazaki, M. Citron, M.B. Podlisny, E.H. Koo, D.B. Teplow, et al. (1996 Jan 17) The role of APP processing and trafficking pathways in the formation of amyloid beta-protein. Ann N Y Acad Sci. 777 57-64.
20. Y. Gong, L. Chang, K.L. Viola, P.N. Lacor, M.P. Lambert, C.E. Finch, et al. (2003 Sep 2) Alzheimer's disease-affected brain: Presence of oligomeric Aβ ligands (ADDLs) suggests a molecular basis for reversible memory loss. Proc Natl Acad Sci USA 100(18), 10417-10422.
21. J. Hardy and D.J. Selkoe (2002 Jul 19) The amyloid hypothesis of Alzheimer's disease: Progress and problems on the road to therapeutics. Science 297(5580), 353-356.
22. K.M. Felsenstein (2000 Dec 1) Aβ modulation: The next generation of AD therapeutics. Ann N Y Acad Sci 920(1), 269-273.
23. D.K. Lahiri, M.R. Farlow, K. Sambamurti, N.H. Greig, E. Giacobini and L.S. Schneider (2003) A critical analysis of new molecular targets and strategies for drug development in Alzheimer's disease. Curr Drug Targets 4(2), 97-112.
24. P.S. Aisen (2005) The development of anti-amyloid therapy for Alzheimer's disease: From secretase modulators to polymerisation inhibitors. CNS Drugs 19(12), 989-996.
25. Y.J. Wang, H.D. Zhou and X.F. Zhou (2006) Clearance of amyloid-beta in Alzheimer's disease: Progress, problems and perspectives. Drug Discov Today 11(19–20), 931-938.
26. J.A. Nicoll, D. Wilkinson, C. Holmes, P. Steart, H. Markham and R.O. Weller (2003) Neuropathology of human Alzheimer disease after immunization with amyloid-beta peptide: A case report. Nat Med 9(4), 448-452.
27. D.B. Schenk, P. Seubert, I. Lieberburg and J. Wallace (2000) Beta-peptide immunization: A possible new treatment for Alzheimer disease. Arch Neurol 57(7), 934-936.
28. S. Gilman, M. Koller, R.S. Black, L. Jenkins, S.G. Griffith, N.C. Fox, et al. (2005 May 10) Clinical effects of Aβ immunization (AN1792) in patients with AD in an interrupted trial. Neurology 64(9), 1553-1562.
29. J.M. Orgogozo, S. Gilman, J.F. Dartigues, B. Laurent, M. Puel, L.C. Kirby, et al. (2003 Jul 8) Subacute meningoencephalitis in a subset of patients with AD after Abeta42 immunization. Neurology 61(1), 46-54.
30. D.B. Schenk, P. Seubert, M. Grundman and R. Black (2005) Aβ immunotherapy: Lessons learned for potential treatment of Alzheimer's disease. Neurodegener Dis 2(5), 255-260.
31. V.M. Lee (1996 Jan 17) Regulation of tau phosphorylation in Alzheimer's disease. Ann N Y Acad Sci 777 107-113.
32. V.M. Lee (1995) Disruption of the cytoskeleton in Alzheimer's disease. Curr Opin Neurobiol 5(5), 663-668.
33. J.Q. Trojanowski and V.M.Y. Lee (2005 Nov 1) The Alzheimer's brain: Finding out what's broken tells us how to fix it. Am J Pathol 167(5), 1183-1188.
34. V.M. Lee and J.Q. Trojanowski (2006) Progress from Alzheimer's tangles to pathological tau points towards more effective therapies now. J Alzheimers Dis 9(3 Suppl), 257-262.
35. M.O. Kwon and P. Herrling (2006) List of drugs in development for neurodegenerative diseases. Update June 2006. Neurodegener Dis 3(3), 148-186.
36. I. Melnikova (2007) Therapies for Alzheimer's disease. Nat Rev Drug Discov 6(5), 341-342.
37. A.D. Roses and M.N. Pangalos (2003) Drug development and Alzheimer disease. Am J Geriatr Psychiatr 11(2), 123-130.
38. Lopez Arrieta, J.M. (2002). Role of meta-analysis of clinical trials for Alzheimer's disease.
39. F. Gualtieri, D. Manetti, M.N. Romanelli and C. Ghelardini (2002) Design and study of piracetam-like nootropics, controversial members of the problematic class of cognition-enhancing drugs. Curr Pharm Des 8(2), 125-138.
40. M.H. Harries, N.A. Samson and J. Cilia (1998) A.J. Hunter. The profile of sabcomeline (SB-202026), a functionally selective M1 receptor partial agonist, in the marmoset. Br J Pharmacol 124(2), 409-415.
41. B. Bontempi, K.T. Whelan, V.B. Risbrough, T.S. Rao, J.J. Buccafusco, G.K. Lloyd, et al. (2001) SIB-1553A, (+/-)-4-[[2-(1-methyl-2-pyrrolidinyl)ethyl]thio]phenol hydrochloride, a subtype-selective ligand for nicotinic acetylcholine receptors with putative cognitive-enhancing properties: Effects on working and reference memory performances in aged rodents and nonhuman primates. J Pharmacol Exp Ther 299(1), 297-306.
42. W.F. Hood, R.P. Compton and J.B. Monahan (1989 Mar 13) d-cycloserine: A ligand for the N-methyl-d-aspartate coupled glycine receptor has partial agonist characteristics. Neurosci Lett 98(1), 91-95.
43. C. Randolph, J.W. Roberts, M.C. Tierney, D. Bravi, M.M. Mouradian and T.N. Chase (1994) d-cycloserine treatment of Alzheimer disease. Alzheimer Dis Assoc Disord 8(3), 198-205.
44. G.E. Tsai, W.E. Falk, J. Gunther and J.T. Coyle (1999) Improved cognition in Alzheimer's disease with short-term d-cycloserine treatment. Am J Psychiatr 156(3), 467-469.
45. A. Mazurov, T. Hauser and C.H. Miller (2006) Selective alpha7 nicotinic acetylcholine receptor ligands. Curr Med Chem 13(13), 1567-1584.
46. S. Oddo and F.M. LaFerla (2006) The role of nicotinic acetylcholine receptors in Alzheimer's disease. J Physiol Paris 99(2–3), 172-179.
47. J.J. Buccafusco, S.R. Letchworth, M. Bencherif and P.M. Lippiello (2005) Long-lasting cognitive improvement with nicotinic receptor agonists: mechanisms of pharmacokinetic-pharmacodynamic discordance. Trends Pharmacol Sci 26(7), 352-360.
48. D.J. Anderson, M. Williams, J.R. Pauly, J.L. Raszkiewicz, J.E. Campbell, G. Rotert, et al. (1995) Characterization of [3H]ABT-418: A novel cholinergic channel ligand. J Pharmacol Exp Ther 273(3), 1434-1441.
49. L.E. Rueter, D.J. Anderson, C.A. Briggs, D.L. Donnelly-Roberts, G.A. Gintant, M. Gopalakrishnan, et al. (2004) ABT-089: Pharmacological properties of a neuronal nicotinic acetylcholine receptor agonist for the potential treatment of cognitive disorders. CNS Drug Rev. 10(2), 167-182.
50. J.S. Schneider, J.P. Tinker, V.M. Van, F. Menzaghi and G.K. Lloyd (1999) Nicotinic acetylcholine receptor agonist SIB-1508Y improves cognitive functioning in chronic low-dose MPTP-treated monkeys. J Pharmacol Exp Ther 290 731-739.
51. J. O'Neill, L.J. Fitten, D.W. Siembieda, K.C. Crawford, E. Halgren, A. Fisher, et al. (1999) Divided attention-enhancing effects of AF102B and THA in aging monkeys. Psychopharmacology (Berl) 143(2), 123-130.
52. J. O'Neill, D.W. Siembieda, K.C. Crawford, E. Halgren, A. Fisher and L.J. Fitten (2003) Reduction in distractibility with AF102B and THA in the macaque. Pharmacol Biochem Behav 76(2), 301-306.
53. A.C. Bartolomeo, H. Morris, J.J. Buccafusco, N. Kille, S. Rosenzweig-Lipson, M.G. Husbands, et al. (2000) The preclinical pharmacological profile of WAY-132983, a potent M1 preferring agonist. J Pharmacol Exp Ther 292(2), 584-596.
54. M.B. Andersen, A. Fink-Jensen, L. Peacock, J. Gerlach, F. Bymaster, J.A. Lundbaek, et al. (2003) The muscarinic M1/M4 receptor agonist xanomeline exhibits antipsychotic-like activity in Cebus apella monkeys. Neuropsychopharmacology 28(6), 1168-1175.
55. R.D. Schwarz, M.J. Callahan, L.L. Coughenour, M.R. Dickerson, J.J. Kinsora and W.J. Lipinski et al (1999) Milameline (CI-979/RU35926): A muscarinic receptor agonist with cognition-activating properties: Biochemical and in vivo characterization. J Pharmacol Exp Ther 291(2), 812-822.
56. A.V. Terry Jr., J.J. Buccafusco, F. Borsini and A. Leusch (2002) Memory-related task performance by aged rhesus monkeys administered the muscarinic M(1)-preferring agonist, talsaclidine. Psychopharmacology (Berl) 162(3), 292-300.
57. M.J. Callahan (1999) Combining tacrine with milameline reverses a scopolamine-induced impairment of continuous performance in rhesus monkeys. Psychopharmacology (Berl) 144(3), 234-238.
58. M. Weinrich, A. Ceci, H.A. Ensinger, W. Gaida, K.D. Mendla, T. Osugi, et al. (2002) Talsaclidine (W2014 FU), a muscarinic M1 receptor agonist for the treatment of Alzheimer's disease. Drug Dev Res 56 321-334.
59. N.R. Mirza, D. Peters and R.G. Sparks (2003) Xanomeline and the antipsychotic potential of muscarinic receptor subtype selective agonists. CNS Drug Rev 9(2), 159-186.
60. N.C. Bodick, W.W. Offen, A.I. Levey, N.R. Cutler, S.G. Gauthier, A. Satlin, et al. (1997) Effects of xanomeline, a selective muscarinic receptor agonist, on cognitive function and behavioral symptoms in Alzheimer disease. Arch Neurol 54(4), 465-473.
61. R. McArthur and F. Borsini (2006) Animal models of depression in drug discovery: A historical perspective. Pharmacol Biochem Behav 84(3), 436-452.
62. A. Fisher, Z. Pittel, R. Haring, N. Bar-Ner, M. Kliger-Spatz and N. Natan et al (2003) M1 muscarinic agonists can modulate some of the hallmarks in Alzheimer's disease: Implications in future therapy. J Mol Neurosci 20(3), 349-356.
63. Orgogozo, J.M. (2006). Vaccination treatment of AD, Alzheimer's Dementia 2, S94.
64. C. Hock, U. Konietzko, J.R. Streffer, J. Tracy, A. Signorell, B. Muller-Tillmanns, et al. (2003 May 22) Antibodies against beta-amyloid slow cognitive decline in Alzheimer's disease. Neuron 38(4), 547-554.
65. P. Leber (2002) Not in our methods, but in our ignorance. Arch Gen Psychiatr 59(3), 279-280.
66. G. McKhann, D. Drachman, M. Folstein, R. Katzman, D. Price and E.M. Stadlan (1984) Clinical diagnosis of Alzheimer's disease: Report of the NINCDS-ADRDA work group under the auspices of department of health and human services task force on Alzheimer's disease. Neurology 34 939-944.
67. R.C. Mohs, D. Knopman, R.C. Petersen, S.H. Ferris, C. Ernesto, M. Grundman, et al. (1997) Development of cognitive instruments for use in clinical trials of antidementia drugs: Additions to the Alzheimer's Disease Assessment Scale that broaden its scope. The Alzheimer's Disease Cooperative Study. Alzheimer Dis Assoc Disord 11(Suppl 2), S13-sS21.
68. F.A. Schmitt, W. Ashford, C. Ernesto, J. Saxton, L.S. Schneider, C.M. Clark, et al. (1997) The severe impairment battery: Concurrent validity and the assessment of longitudinal change in Alzheimer's disease. The Alzheimer's Disease Cooperative Study. Alzheimer Dis Assoc Disord 11(Suppl 2), S51-sS56.
69. L.S. Schneider, J.T. Olin, R.S. Doody, C.M. Clark, J.C. Morris, B. Reisberg, et al. (1997) Validity and reliability of the Alzheimer's Disease Cooperative Study-Clinical Global Impression of Change. The Alzheimer's Disease Cooperative Study. Alzheimer Dis. Assoc. Disord. 11(Suppl. 2), S22-sS32.
70. D. Galasko, D. Bennett, M. Sano, C. Ernesto, R. Thomas, M. Grundman, et al. (1997) An inventory to assess activities of daily living for clinical trials in Alzheimer's disease. The Alzheimer's Disease Cooperative Study. Alzheimer Dis Assoc Disord 11(Suppl. 2), S33-sS39.
71. R. Katz (2004) Biomarkers and surrogate markers: An FDA perspective. NeuroRx 1(2), 189-195.
72. L.J. Thal, K. Kantarci, E.M. Reiman, W.E. Klunk, M.W. Weiner, H. Zetterberg, et al. (2006) The role of biomarkers in clinical trials for Alzheimer disease. Alzheimer Dis Assoc Disord 20(1), 6-15.
73. C. Bernard (1865) An Introduction to the Study of Experimental Medicine. New York: Dover Publications Inc.
74. L.M. Friedman, C.D. Furberg and D.L. DeMets (1998) Fundamentals of Clinical Trials. 3rd ed New York: Springer
75. T.R. Fleming (2000) Surrogate end points in cardiovascular disease trials. Am Heart J 139(4), S193-sS196.
76. R.J. Temple (1995) A regulatory authority's opinion about surrogate endpoints. W.S. Nimmo, G.T. Tucker (Eds) Clinical Measurement in Drug Evaluation New York: John Wiley & Sons
77. R.L. Prentice (1989) Surrogate endpoints in clinical trials: Definition and operational criteria. Stat Med 8(4), 431-440.
78. M.D. Lindner, M.A. Plone, J.M. Francis and C.K. Cain (1999) Chronic morphine reduces pain-related disability in a rodent model of chronic, inflammatory pain. Exp Clin Psychopharmacol 7(3), 187-197.
79. T.R. Fleming and D.L. DeMets (1996 Oct 1) Surrogate end points in clinical trials: Are we being misled? Ann Intern Med 125(7), 605-613.
80. D.H. Small and R. Cappai (2006) Alois Alzheimer and Alzheimer's disease: A centennial perspective. J Neurochem 99(3), 708-710.
81. Z.S. Khachaturian (1985) Diagnosis of Alzheimer's disease. Arch Neurol (42), 1097-1105.
82. T. Gomezisla, R. Hollister, H. West, S. Mui, J.H. Growdon, R.C. Petersen, et al. (1997) Neuronal loss correlates with but exceeds neurofibrillary tangles in Alzheimer's disease. Ann Neurol 41(1), 17-24.
83. P.V. Arriagada, J.H. Growdon, E.T. Hedley-Whyte and B.T. Hyman (1992) Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer's disease. Neurology 42(3 Pt 1), 631-639.
84. H.A. Crystal, D. Dickson, P. Davies, D. Masur, E. Grober and R.B. Lipton (2000) The relative frequency of “dementia of unknown etiology” increases with age and is nearly 50% in nonagenarians. Arch Neurol 57(5), 713-719.
85. H. Petrovitch, L.R. White, G.W. Ross, S.C. Steinhorn, C.Y. Li, K.H. Masaki, et al. (2001 Aug 24) Accuracy of clinical criteria for AD in the Honolulu-Asia Aging Study, a population-based study. Neurology 57(2), 226-234.
86. H. Crystal, D. Dickson, P. Fuld, D. Masur, R. Scott, M. Mehler, et al. (1988) Clinico-pathologic studies in dementia: Nondemented subjects with pathologically confirmed Alzheimer's disease. Neurology 38(11), 1682-1687.
87. D.W. Dickson, H.A. Crystal, L.A. Mattiace, D.M. Masur, A.D. Blau, P. Davies, et al. (1992) Identification of normal and pathological aging in prospectively studied nondemented elderly humans. Neurobiol Aging 13(1), 179-189.
88. J.W. Geddes, T.L. Tekirian, N.S. Soultanian, J.W. Ashford, D.G. Davis and W.R. Markesbery (1997) Comparison of neuropathologic criteria for the diagnosis of Alzheimer's disease. Neurobiol Aging 18(4 Suppl), S99-sS105.
89. F.A. Schmitt, D.G. Davis, D.R. Wekstein, C.D. Smith, J.W. Ashford and W.R. Markesbery (2000 Sep 8) “Preclinical” AD revisited: Neuropathology of cognitively normal older adults. Neurology 55(3), 370-376.
90. D.G. Davis, F.A. Schmitt, D.R. Wekstein and W.R. Markesbery (1999) Alzheimer neuropathologic alterations in aged cognitively normal subjects. J Neuropathol Exp Neurol 58(4), 376-388.
91. C.A. McLean, R.A. Cherny, F.W. Fraser, S.J. Fuller, M.J. Smith, K. Beyreuther, et al. (1999) Soluble pool of Abeta amyloid as a determinant of severity of neurodegeneration in Alzheimer's disease. Ann Neurol 46(6), 860-866.
92. L.F. Lue, Y.M. Kuo, A.E. Roher, L. Brachova, Y. Shen, L. Sue, et al. (1999) Soluble amyloid beta peptide concentration as a predictor of synaptic change in Alzheimer's disease. Am J Pathol 155(3), 853-862.
93. R.F. Thompson (2005) In search of memory traces. Annu Rev Psychol 56 1-23.
94. D.S. Olton (1989) Mnemonic functions of the hippocampus: Past, present and future. L.R. Squire, E. Lindenlaub (Eds) The Biology of Memory New York, NY: F.D. Schattauer Verlag 427-440.
95. J. Ledoux (2003) The emotional brain, fear, and the amygdale. Cell Mol Neurobiol 23 727-738.
96. R.G. Morris and M.D. Rugg (2004) Messing about in memory. Nat. Neurosci. 7 1171-1173.
97. E.R. Kandel (2001 Nov 2) The molecular biology of memory storage: A dialogue between genes and synapses. Science 294 1030-1038.
98. M. Mishkin, F. Vargha-Khadem and D.G. Gadian (1998) Amnesia and the organization of the hippocampal system. Hippocampus 8 212-216.
99. L.R. Squire and S.M. Zola-Morgan (1988) Memory: Brain systems and behavior. TINS 11 170-175.
100. R. Morris (1984) Developments of a water-maze procedure for studying spatial learning in the rat. J Neurosci Methods 11 47-60.
101. J. O'Keefe and L. Nadel (1978) The Hippocampus as a Cognitive Map. Oxford: Oxford University Press
102. L.E. Jarrard (1991) On the neural bases of the spatial mapping system: Hippocampus vs. hippocampal formation. Hippocampus 1 236-239.
103. W.A. Suzuki and D.G. Amaral (2004) Functional neuroanatomy of the medial temporal lobe memory system. Cortex 40 220-222.
104. M.P. Witter and E.I. Moser (2006) Spatial representation and the architecture of the entorhinal cortex. Trends Neurosci 29 671-678.
105. S. Leutgeb, J.K. Leutgeb, M.B. Moser and E.I. Moser (2005) Place cells, spatial maps and the population code for memory. Curr Opin Neurobiol 15 738-746.
106. H. Eichenbaum (2000) A cortical-hippocampal system for declarative memory. Nat Rev Neurosci 1 41-50.
107. H.J. Spiers, N. Burgess, E.A. Maguire, S.A. Baxendale, T. Hartley, P.J. Thompson, et al. (2001) Unilateral temporal lobectomy patients show lateralized topographical and episodic memory deficits in a virtual town. Brain 124 2476-2489.
108. E.A. Maguire, C.D. Frith, N. Burgess, J.G. Donnett and J. O'Keefe (1998) Knowing where things are parahippocampal involvement in encoding object locations in virtual large-scale space. J Cogn Neurosci 10 61-76.
109. W.A. Suzuki (2003 Apr 10) Declarative versus episodic: Two theories put to the test. Neuron 38 5-7.
110. L.R. Squire and S.M. Zola (1998) Episodic memory, semantic memory, and amnesia. Hippocampus 8 205-211.
111. E.T. Rolls, J. Xiang and L. Franco (2005) Object, space, and object-space representations in the primate hippocampus. J Neurophysiol 94 833-844.
112. D. Gaffan (1991) Spatial organization of episodic memory. Hippocampus 1 262-264.
113. N.J. Fortin, S.P. Wright and H. Eichenbaum (2004 Sep 9) Recollection-like memory retrieval in rats is dependent on the hippocampus. Nature 431 188-191.
114. L. Malkova, M. Mishkin and J. Bachevalier (1995) Long-term effects of selective neonatal temporal lobe lesions on learning and memory in monkeys. Behav Neurosci 109(2), 212-226.
115. A. Petrulis, P. Alvarez and H. Eichenbaum (2005) Neural correlates of social odor recognition and the representation of individual distinctive social odors within entorhinal cortex and ventral subiculum. Neuroscience 130 259-274.
116. B. Kolb (2005) Neurological Models. I.Q. Whishaw, B. Kolb (Eds) The Behavior of the laboratory Rat New York: Oxford University Press 449-461.
117. R.T. Bartus, C. Flicker, R.L. Dean, M. Pontecorvo, J.C. Figueiredo and S.K. Fisher (1985) Selective memory loss following nucleus basalis lesions: Long term behavioral recovery despite persistent cholinergic deficiencies. Pharmacol Biochem Behav 23 125-135.
118. I.Q. Whishaw (1989) Dissociating performance and learning deficits on spatial navigation tasks in rats subjected to cholinergic muscarinic blockade. Brain Res Bull 23 347-358.
119. M.A. Geyer and A. Markou (1995) Animal models of psychiatric disorders. F.E. Bloom, D.J. Kupfer (Eds) Psychopharmacology, The Fourth Generation of Progress New York: Raven Press 787-798.
120. P. Willner (1994) Behavioural Models in Psychopharmacology: Theoretical, Industrial and Clinical Perspectives. Cambridge: Cambridge University Press
121. B.D. Berger and L. Stein (1969) An analysis of the learning deficits produced by scopolamine. Psychopharmacologia 14(4), 271-283.
122. S. Patel and P.N. Tariot (1991) Pharmacologic models of Alzheimer's disease. Psychiatr Clin North Am 14(2), 287-308.
123. G.C. Preston, C. Ward, C.R. Lines, P. Poppleton, J.R. Haigh and M. Traub (1989) Scopolamine and benzodiazepine models of dementia: Cross-reversals by Ro 15-1788 and physostigmine. Psychopharmacology (Berl) 98(4), 487-494.
124. D.F. Wozniak, J.W. Olney, L. Kettinger III., M. Price and J.P. Miller (1990) Behavioral effects of MK-801 in the rat. Psychopharmacology (Berl) 101(1), 47-56.
125. J.D. Jentsch and R.H. Roth (1999) The neuropsychopharmacology of phencyclidine: From NMDA receptor hypofunction to the dopamine hypothesis of schizophrenia. Neuropsychopharmacology 20(3), 201-225.
126. Higgins, G.A. and Lashley, K.S. (1950). In search of the engram. Society of Experimental Biology Symposium No. 4: Physiological Mechanisms in Animal Behavior. Cambridge University Press, Cambridge. pp. 287–313.
127. R.W. Sperry (1961) Cerebral control and behavior. Science 133 1749-1757.
128. S.B. Dunnett (1985) Comparative effects of cholinergic drugs and lesions of nucleus basalis or fimbria-fornix on delayed matching in rats. Psychopharmacology 87 357-363.
129. D.L. Kirkby (1998) Characterization of perforant path lesions in rodent models of memory and attention. Eur J Neurosci 10(3), 823-838.
130. T. Myhrer (1993) Animal models of Alzheimer's disease: Glutamatergic denervation as an alternative approach to cholinergic denervation. Neurosci Biobehav Rev 17(2), 195-202.
131. L.E. Jarrard (1993) On the role of the hippocampus in learning and memory in the rat. Behav Neural Biol 60(1), 9-26.
132. R. Galani, S. Obis, E. Coutureau, L. Jarrard and J.C. Cassel (2002) A comparison of the effects of fimbria-fornix, hippocampal, or entorhinal cortex lesions on spatial reference and working memory in rats: Short versus long postsurgical recovery period. Neurobiol Learn Mem 77 1-16.
133. R.D. Brinton and J.M. Wang (2006) Therapeutic potential of neurogenesis for prevention and recovery from Alzheimer's disease: Allopregnanolone as a proof of concept neurogenic agent. Curr Alzheimer Res 3 185-190.
134. N.R. Melvin, S.C. Spanswick, H. Lehmann and R.J. Sutherland (2007) Differential neurogenesis in the adult rat dentate gyrus: An identifiable zone that consistently lacks neurogenesis. Eur J Neurosci 25(4), 1023-1029.
135. H. Frielingsdorf, D.R. Simpson, L.J. Thal and D.P. Pizzo (2007) Nerve growth factor promotes survival of new neurons in the adult hippocampus. Neurobiol Dis 26 47-55.
136. D.C. Lagace, M.A. Noonan and A.J. Eisch (2007) Hippocampal neurogenesis: A matter of survival. Am J Psychiatr 164 205.
137. G.A. Elder, G.R. De and M.A. Gama Sosa (2006) Research update: Neurogenesis in adult brain and neuropsychiatric disorders. Mt. Sinai J Med 73 931-940.
138. N.L. Chevallier, S. Soriano, D.E. Kang, E. Masliah, G. Hu and E.H. Koo (2005) Perturbed neurogenesis in the adult hippocampus associated with presenilin-1 A246E mutation. Am J Pathol 167 151-159.
139. N.J. Haughey, A. Nath, S.L. Chan, A.C. Borchard, M.S. Rao and M.P. Mattson (2002) Disruption of neurogenesis by amyloid beta-peptide, and perturbed neural progenitor cell homeostasis, in models of Alzheimer's disease. J Neurochem 83 1509-1524.
140. J. Kelleher-Andersson (2006) Discovery of neurogenic, Alzheimer's disease therapeutics. Curr Alzheimer Res 3 55-62.
141. G. Gouras and H. Fillit (2006) Neurogenesis as a therapeutic strategy for cognitive aging and Alzheimer's disease. Curr Alzheimer Res 3 3.
142. M. Becker, V. Lavie and B. Solomon (2007 Jan 30) Stimulation of endogenous neurogenesis by anti-EFRH immunization in a transgenic mouse model of Alzheimer's disease. Proc Natl Acad Sci USA 104 1691-1696.
143. P.B. Rosenberg (2005) Clinical aspects of inflammation in Alzheimer's disease. Int Rev Psychiatr 17 503-514.
144. M.P. Mattson, W. Duan, R. Wan and Z. Guo (2004) Prophylactic activation of neuroprotective stress response pathways by dietary and behavioral manipulations. NeuroRx 1 111-116.
145. K. Sugaya, A. Alvarez, A. Marutle, Y.D. Kwak and E. Choumkina (2006) Stem cell strategies for Alzheimer's disease therapy. Panminerva Med 48 87-96.
146. T.L. Limke and M.S. Rao (2003) Neural stem cell therapy in the aging brain: pitfalls and possibilities. J Hematother Stem Cell Res 12 615-623.
147. Shors, T.J. (2003 Dec 10). Can new neurons replace memories lost? Sci Aging Knowledge Environ; e35.
148. P.R. Rapp, E.C. Stack and M. Gallagher (1999 Jan 25) Morphometric studies of the aged hippocampus: I. Volumetric analysis in behaviorally characterized rats. J Comp Neurol 403(4), 459-470.
149. K. Sugaya, R. Greene, D. Personett, M. Robbins, C. Kent, D. Bryan, et al. (1998) Septo-hippocampal cholinergic and neurotrophin markers in age-induced cognitive decline. Neurobiol Aging 19(4), 351-361.
150. T.D. Smith, M.M. Adams, M. Gallagher, J.H. Morrison and P.R. Rapp (2000 Sep 1) Circuit-specific alterations in hippocampal synaptophysin immunoreactivity predict spatial learning impairment in aged rats. J Neurosci 20(17), 6587-6593.
151. M.G. Baxter and M. Gallagher (1996) Neurobiological substrates of behavioral decline: Models and data analytic strategies for individual differences in aging. Neurobiol Aging 17(3), 491-495.
152. W. Fischer, K.S. Chen, F.H. Gage and A. Bjorklund (1992) Progressive decline in spatial learning and integrity of forebrain cholinergic neurons in rats during aging. Neurobiol Aging 13 9-23.
153. E. Drapeau, W. Mayo, C. Aurousseau, M.M. Le, P.V. Piazza and D.N. Abrous (2003 Nov 25) Spatial memory performances of aged rats in the water maze predict levels of hippocampal neurogenesis. Proc Natl Acad Sci USA 100(24), 14385-14390.
154. J.L. Bizon, H.J. Lee and M. Gallagher (2004) Neurogenesis in a rat model of age-related cognitive decline. Aging Cell 3(4), 227-234.
155. M.D. Lindner (1997) Reliability, distribution, and validity of age-related cognitive deficits in the Morris water maze. Neurobiol Learn Memory 68(3), 203-220.
156. M.D. Lindner, J.B. Hogan, R.G. Krause, F. Machet, C. Bourin, D.B. Hodges Jr., et al. (2006 Oct 2) Soluble Aβ and cognitive function in aged F-344 rats and Tg2576 mice. Behav Brain Res 173(1), 62-75.
157. M. Grundman, R.C. Petersen, S.H. Ferris, R.G. Thomas, P.S. Aisen, D.A. Bennett, et al. (2004) Mild cognitive impairment can be distinguished from Alzheimer disease and normal aging for clinical trials. Arch Neurol 61(1), 59-66.
158. B. Pillon, B. Dubois, A. Ploska and Y. Agid (1991) Severity and specificity of cognitive impairment in Alzheimer's, Huntington's, and Parkinson's diseases and progressive supranuclear palsy. Neurology 41 634-643.
159. N. Bons, F. Rieger, D. Prudhomme, A. Fisher and K.H. Krause (2006) Microcebus murinus: A useful primate model for human cerebral aging and Alzheimer's disease? Genes Brain Behav 5(2), 120-130.
160. E. Head, K. Moffat, P. Das, F. Sarsoza, W.W. Poon, G. Landsberg, et al. (2005) Beta-amyloid deposition and tau phosphorylation in clinically characterized aged cats. Neurobiol Aging 26(5), 749-763.
161. E. Head, E.G. Barrett, M.P. Murphy, P. Das, M. Nistor, F. Sarsoza, et al. (2006 Apr 5) Immunization with fibrillar Abeta(1-42) in young and aged canines: Antibody generation and characteristics, and effects on CSF and brain Abeta. Vaccine 24(15), 2824-2834.
162. M.J. Ball, J. MacGregor, I.M. Fyfe, S.I. Rapoport and E.D. London (1983) Paucity of morphological changes in the brains of ageing beagle dogs: Further evidence that Alzheimer lesions are unique for primate central nervous system. Neurobiol Aging 4(2), 127-131.
163. D. Kirik and A. Bjorklund (2003) Modeling CNS neurodegeneration by overexpression of disease-causing proteins using viral vectors. Trends Neurosci 26 386-392.
164. D. Kirik, L.E. Annett, C. Burger, N. Muzyczka, R.J. Mandel and A. Bjorklund (2003 Mar 4) Nigrostriatal alpha-synucleinopathy induced by viral vector-mediated overexpression of human alpha-synuclein: a new primate model of Parkinson's disease. Proc Natl Acad Sci USA 100 2884-2889.
165. L.P. de Almeida, C.A. Ross, D. Zala, P. Aebischer and N. Deglon (2002 May 1) Lentiviral-mediated delivery of mutant huntingtin in the striatum of rats induces a selective neuropathology modulated by polyglutamine repeat size, huntingtin expression levels, and protein length. J Neurosci 22 3473-3483.
166. T. Carlsson, T. Bjorklund and D. Kirik (2006) Restoration of the striatal dopamine synthesis for Parkinson's disease: Viral vector-mediated enzyme replacement strategy. Curr Gene Ther 7 109-120.
167. A. Mouri, Y. Noda, H. Hara, H. Mizoguchi, T. Tabira and T. Nabeshima (2007) Oral vaccination with a viral vector containing Aβ cDNA attenuates age-related Aβ accumulation and memory deficits without causing inflammation in a mouse Alzheimer model. FASEB J 21(9), 2135-2148.
168. Y. Gong, E.M. Meyer, C.A. Meyers, R.L. Klein, M.A. King and J.A. Hughes (2006) Memory-related deficits following selective hippocampal expression of Swedish mutation amyloid precursor protein in the rat. Exp Neurol 200(2), 371-377.
169. L.F. Wong, L. Goodhead, C. Prat, K.A. Mitrophanous, S.M. Kingsman and N.D. Mazarakis (2006) Lentivirus-mediated gene transfer to the central nervous system: Therapeutic and research applications. Hum Gene Ther 17 1-9.
170. K. Hsiao, P. Chapman, S. Nilsen, C. Eckman, Y. Harigaya, S. Younkin, et al. (1996 Oct 4) Correlative memory deficits, Abeta elevation, and amyloid plaques in transgenic mice. Science 274(5284), 99-102.
171. D.L. King and G.W. Arendash (2002) Behavioral characterization of the Tg2576 transgenic model of Alzheimer's disease through 19 months. Physiol Behav 75(5), 627-642.
172. M.M. Esiri and G.K. Wilcock (1984) The olfactory bulbs in Alzheimer's disease. J Neurol Neurosurg Psychiatr 47(1), 56-60.
173. D.P. Devanand, K.S. Michaels-Marston, X. Liu, G.H. Pelton, M. Padilla, K. Marder, et al. (2000) Olfactory deficits in patients with mild cognitive impairment predict Alzheimer's disease at follow-up. Am J Psychiatr 157(9), 1399-1405.
174. R.L. Doty, P.F. Reyes and T. Gregor (1987) Presence of both odor identification and detection deficits in Alzheimer's disease. Brain Res Bull 18(5), 597-600.
175. C.D. Morgan, S. Nordin and C. Murphy (1995) Odor identification as an early marker for Alzheimer's disease: Impact of lexical functioning and detection sensitivity. J Clin Exp Neuropsychol 17(5), 793-803.
176. C. Murphy, M.M. Gilmore, C.S. Seery, D.P. Salmon and B.R. Lasker (1990) Olfactory thresholds are associated with degree of dementia in Alzheimer's disease. Neurobiol Aging 11(4), 465-469.
177. McArthur, R.A., Franklin, S.F., Goodwin, A., Oostveen, J., and Buhl, A.E. (2000). APP-overexpressing transgenic mice (Tg2576) are not impaired in the acquisition of an olfactory discrimination, 30th Annual Meeting Society for Neuroscience, New Orleans, November 4–9.
178. D. Games, D. Adams, R. Alessandrini, R. Barbour, P. Berthelette, C. Blackwell, et al. (1995 Feb 9) Alzheimer-type neuropathology in transgenic mice overexpressing V717F beta-amyloid precursor protein. Nature 373(6514), 523-527.
179. J.C. Dodart, H. Meziane, C. Mathis, K.R. Bales, S.M. Paul and A. Ungerer (1999) Behavioral disturbances in transgenic mice overexpressing the V717F beta-amyloid precursor protein. Behav Neurosci 113(5), 982-990.
180. G.W. Arendash, D.L. King, M.N. Gordon, D. Morgan, J.M. Hatcher, C.E. Hope, et al. (2001 Feb 9) Progressive, age-related behavioral impairments in transgenic mice carrying both mutant amyloid precursor protein and presenilin-1 transgenes. Brain Res 891(1–2), 42-53.
181. G.W. Arendash, M.N. Gordon, D.M. Diamond, L.A. Austin, J.M. Hatcher, P. Jantzen, et al. (2001) Behavioral assessment of Alzheimer's transgenic mice following long-term Abeta vaccination: task specificity and correlations between Abeta deposition and spatial memory. DNA Cell Biol 20(11), 737-744.
182. S. Oddo, A. Caccamo, J.D. Shepherd, M.P. Murphy, T.E. Golde, R. Kayed, et al. (2003 Jul 31) Triple-transgenic model of Alzheimer's disease with plaques and tangles: intracellular Aβ and synaptic dysfunction. Neuron 39(3), 409-421.
183. S. Oddo, A. Caccamo, M. Kitazawa, B.P. Tseng and F.M. LaFerla (2003) Amyloid deposition precedes tangle formation in a triple transgenic model of Alzheimer's disease. Neurobiol Aging 24(8), 1063-1070.
184. L.M. Billings, S. Oddo, K.N. Green, J.L. McGaugh and F.M. LaFerla (2005 Mar 3) Intraneuronal Aβ causes the onset of early Alzheimer's disease-related cognitive deficits in transgenic mice. Neuron 45(5), 675-688.
185. M.W. Decker and J.L. McGaugh (1989 Jan 16) Effects of concurrent manipulations of cholinergic and noradrenergic function on learning and retention in mice. Brain Res 477(1–2), 29-37.
186. R.A. Jensen, J.L. Martinez Jr., B.J. Vasquez and J.L. McGaugh (1979 Jun 28) Benzodiazepines alter acquisition and retention of an inhibitory avoidance response in mice. Psychopharmacology (Berl) 64 125-126.
187. J.L. McGaugh and L. Cahill (1997) Interaction of neuromodulatory systems in modulating memory storage. Behav Brain Res 83(1–2), 31-38.
188. L. Cahill and J.L. McGaugh (1998) Mechanisms of emotional arousal and lasting declarative memory. Trends Neurosci 21 294-299.
189. M.R. Tinsley and M.S. Fanselow (2005) Fear. I.Q. Whishaw, B. Kolb (Eds) The Behavior of the Laboratory Rat New York: Oxford University Press 410-421.
190. V. Rau, J.P. DeCola and M.S. Fanselow (2005) Stress-induced enhancement of fear learning: An animal model of posttraumatic stress disorder. Neurosci Biobehav Rev 29 1207-1223.
191. E.A. Mayer and M.S. Fanselow (2003) Dissecting the components of the central response to stress. Nat Neurosci 6 1011-1012.
192. D.G. Mumby (2005) Object Recognition. I.Q. Whishaw, B. Kolb (Eds) The Behavior of the Laboratory Rat New York: Oxford University Press 383-391.
193. R.N. Hughes (1997) Intrinsic exploration in animals: Motives and measurement. Behavioural Processes 41 213-226.
194. D.G. Mumby (2001 Dec 14) Perspectives on object-recognition memory following hippocampal damage: Lessons from studies in rats. Behav Brain Res 127(1–2), 159-181.
195. T.J. Bussey, J. Duck, J.L. Muir and J.P. Aggleton (2000 Jun 15) Distinct patterns of behavioural impairments resulting from fornix transection or neurotoxic lesions of the perirhinal and postrhinal cortices in the rat. Behav Brain Res 111(1–2), 187-202.
196. P. Jackson-Smith, R.P. Kesner and A.A. Chiba (1993) Continuous recognition of spatial and nonspatial stimuli in hippocampal-lesioned rats. Behav Neural Biol 59(2), 107-119.
197. J.A. Ainge, C. Heron-Maxwell, P. Theofilas, P. Wright, H.L. de and E.R. Wood (2006 Feb 15) The role of the hippocampus in object recognition in rats: Examination of the influence of task parameters and lesion size. Behav Brain Res 167(1), 183-195.
198. J.P. Aggleton and M.W. Brown (1999) Episodic memory, amnesia, and the hippocampal-anterior thalamic axis. Behav Brain Sci 22(3), 425-444.
199. M.W. Brown and J.P. Aggleton (2001) Recognition memory: What are the roles of the perirhinal cortex and hippocampus? Nat Rev Neurosci 2 51-61.
200. S.B. Dunnett (1989) Comparison of short-term memory deficits in animal models of aging using an operant delayed response task in rats. L.R. Squire, E. Lindenlaub (Eds) The Biology of Memory New York, NY: F.K. Schattauer Verlag 581-603.
201. R.E. Hampson, C.J. Heyser and S.A. Deadwyler (1993) Hippocampal cell firing correlates of delayed-match-to-sample performance in the rat. Behav Neurosci 107(5), 715-739.
202. S.A. Deadwyler, T. Bunn and R.E. Hampson (1996) Hippocampal ensemble activity during spatial delayed-nonmatch-to-sample performance in rats. J Neurosci 16 354-372.
203. S.A. Deadwyler and R.E. Hampson (2004) Differential but complementary mnemonic functions of the hippocampus and subiculum. Neuron 42 465-476.
204. D.S. Olton, J.T. Becker and G.E. Handelmann (1979) Hippocampus, space, and memory. Behav Brain Sci 2 313-365.
205. C.G. Wible, R.L. Findling, M. Shapiro, E.J. Lang, S. Crane and D.S. Olton (1986 Dec 3) Mnemonic correlates of unit activity in the hippocampus. Brain Res 399(1), 97-110.
206. R.K. Zeldin and D.S. Olton (1986) Rats acquire spatial learning sets. J Exp Psychol Anim Behav Process 12 412-419.
207. R.G. Morris, J.J. Hagan and J.N. Rawlins (1986) Allocentric spatial learning by hippocampectomised rats: A further test of the spatial mapping and working memory theories of hippocampal function. Q J Exp Psychol [B] 38 365-395.
208. R.G. Morris (1991) Distinctive computations and relevant associative processes: Hippocampal role in processing, retrieval, but not storage of allocentric spatial memory. Hippocampus 1 287-290.
209. G. Chen, K.S. Chen, J. Knox, J. Inglis, A. Bernard, S.J. Martin, et al. (2000 Dec 21) A learning deficit related to age and beta-amyloid plaques in a mouse model of Alzheimer's disease. Nature 408(6815), 975-979.
210. A.M. Paolo, B.N. Axelrod, A.I. Troster, K.T. Blackwell and W.C. Koller (1996) Utility of a Wisconsin Card Sorting Test short form in persons with Alzheimer's and Parkinson's disease. J Clin Exp Neuropsychol 18(6), 892-897.
211. R. Dias, T.W. Robbins and A.C. Roberts (1996) Primate analogue of the Wisconsin Card Sorting Test: Effects of excitotoxic lesions of the prefrontal cortex in the marmoset. Behav Neurosci 110(5), 872-886.
212. R. Dias, T.W. Robbins and A.C. Roberts (1996 Mar 7) Dissociation in prefrontal cortex of affective and attentional shifts. Nature 380(6569), 69-72.
213. M.R. Stefani, K. Groth and B. Moghaddam (2003) Glutamate receptors in the rat medial prefrontal cortex regulate set-shifting ability. Behav Neurosci 117(4), 728-737.
214. J.M. Birrell and V.J. Brown (2000 Jun 1) Medial frontal cortex mediates perceptual attentional set shifting in the rat. J Neurosci 20(11), 4320-4324.
215. C.P. Duncan (1949) The retroactive effect of electroshock on learning. J Comp Physiol Psychol 42 32-44.
216. M.E. Jarvik and R. Kopp (1967) An improved one-trial passive avoidance learning situation. Psychol Rep 21 221-224.
217. M.W. Luttges and J.L. McGaugh (1967) Permanence of retrograde amnesia produced by electroconvulsive shock. Science 156 408-410.
218. R.E. Hampson, T.P. Pons, T.R. Stanford and S.A. Deadwyler (2004 Mar 2) Categorization in the monkey hippocampus: A possible mechanism for encoding information into memory. Proc Natl Acad Sci USA 101 3184-3189.
219. D.J. Freedman, M. Riesenhuber, T. Poggio and E.K. Miller (2003 Jun 15) A comparison of primate prefrontal and inferior temporal cortices during visual categorization. J Neurosci 23 5235-5246.
220. E.K. Miller, A. Nieder, D.J. Freedman and J.D. Wallis (2003) Neural correlates of categories and concepts. Curr Opin Neurobiol 13 198-203.
221. L.J. Porrino, J.B. Daunais, G.A. Rogers, R.E. Hampson and S.A. Deadwyler (2005) Facilitation of task performance and removal of the effects of sleep deprivation by an ampakine (CX717) in nonhuman primates. PLoS Biol 3 e299.
222. T.G. Aigner, S.J. Mitchell, J.P. Aggleton, M.R. DeLong, R.G. Struble, D.L. Price, et al. (1987) Effects of scopolamine and physostigmine on recognition memory in monkeys with ibotenic-acid lesions of the nucleus basalis of Meynert. Psychopharmacology (Berl) 92(3), 292-300.
223. J. Fournier, R. Steinberg, T. Gauthier, P.E. Keane, U. Guzzi, F.X. Coude, et al. (1993) Protective effects of SR 57746A in central and peripheral models of neurodegenerative disorders in rodents and primates. Neuroscience 55(3), 629-641.
224. A. Easton, R.M. Ridley, H.F. Baker and D. Gaffan (2002) Unilateral lesions of the cholinergic basal forebrain and fornix in one hemisphere and inferior temporal cortex in the opposite hemisphere produce severe learning impairments in rhesus monkeys. Cereb Cortex 12(7), 729-736.
225. R.M. Ridley, S. Gribble, B. Clark, H.F. Baker and A. Fine (1992) Restoration of learning ability in fornix-transected monkeys after fetal basal forebrain but not fetal hippocampal tissue transplantation. Neuroscience 48(4), 779-792.
226. A.C. Roberts, T.W. Robbins, B.J. Everitt, G.H. Jones, T.E. Sirkia, J. Wilkinson, et al. (1990) The effects of excitotoxic lesions of the basal forebrain on the acquisition, retention and serial reversal of visual discrimations in marmosets. Neuroscience 34(2), 311-329.
227. S. Zola-Morgan and L.R. Squire (1986) Memory impairment in monkeys following lesions limited to the hippocampus. Behav Neurosci 100(2), 155-160.
228. T.G. Aigner and M. Mishkin (1986) The effects of physostigmine and scopolamine on recognition memory in monkeys. Behav Neural Biol 45(1), 81-87.
229. N.M. Rupniak, M.J. Field, N.A. Samson, M.J. Steventon and S.D. Iversen (1990) Direct comparison of cognitive facilitation by physostigmine and tetrahydroaminoacridine in two primate models. Neurobiol Aging 11(6), 609-613.
230. M.A. Taffe, M.R. Weed and L.H. Gold (1999 Oct 25) Scopolamine alters rhesus monkey performance on a novel neuropsychological test battery. Brain Res Cogn Brain Res 8(3), 203-212.
231. J.A. Harder, A.A. Aboobaker, T.C. Hodgetts and R.M. Ridley (1998) Learning impairments induced by glutamate blockade using dizocilpine (MK-801) in monkeys. Br J Pharmacol 125(5), 1013-1018.
232. N.M. Rupniak, M. Duchnowski, S.J. Tye, G. Cook and S.D. Iversen (1992) Failure of d-cycloserine to reverse cognitive disruption induced by scopolamine or phencyclidine in primates. Life Sci 50(25), 1959-1962.
233. R.T. Bartus (1979 Nov 30) Physostigmine and recent memory: Effects in young and aged nonhuman primates. Science 206(4422), 1087-1089.
234. W.J. Jackson, J.J. Buccafusco, A.V. Terry, D.J. Turk and D.K. Rush (1995) Velnacrine maleate improves delayed matching performance by aged monkeys. Psychopharmacology (Berl) 119(4), 391-398.
235. M.A. Prendergast, A.V. Terry Jr., W.J. Jackson, K.C. Marsh, M.W. Decker, S.P. Arneric, et al. (1997) Improvement in accuracy of delayed recall in aged and non-aged, mature monkeys after intramuscular or transdermal administration of the CNS nicotinic receptor agonist ABT-418. Psychopharmacology (Berl) 130(3), 276-284.
236. J. Birks and R.J. Harvey (2006) Donepezil for dementia due to Alzheimer's disease. Cochrane Database Syst Rev (1), (CD001190)
237. A. Burns, M. Rossor, J. Hecker, S. Gauthier, H. Petit, H.J. Moller, et al. (1999) The effects of donepezil in Alzheimer's disease – Results from a multinational trial. Dement Geriatr Cogn Disord 10(3), 237-244.
238. S.L. Rogers and L.T. Friedhoff (1996) The efficacy and safety of donepezil in patients with Alzheimer's disease: Results of a US multicentre, randomized, double-blind, placebo-controlled trial, The Donepezil Study Group. Dementia 7(6), 293-303.
239. H.P. Matthews, J. Korbey, D.G. Wilkinson and J. Rowden (2000) Donepezil in Alzheimer's disease: Eighteen month results from Southampton Memory Clinic. Int J Geriatr Psychiatr 15(8), 713-720.
240. S.L. Rogers, R.S. Doody, R.D. Pratt and J.R. Ieni (2000) Long-term efficacy and safety of donepezil in the treatment of Alzheimer's disease: Final analysis of a US multicentre open-label study. Eur Neuropsychopharmacol 10(3), 195-203.
241. P. Rocca, E. Cocuzza, L. Marchiaro and F. Bogetto (2002) Donepezil in the treatment of Alzheimer's disease: Long-term efficacy and safety. Prog Neuropsychopharmacol Biol Psychiatr 26(2), 369-373.
242. D.G. Wilkinson, A.P. Passmore, R. Bullock, S.W. Hopker, R. Smith, F.C. Potocnik, et al. (2002) A multinational, randomised, 12-week, comparative study of donepezil and rivastigmine in patients with mild to moderate Alzheimer's disease. Int J Clin Pract 56(6), 441-446.
243. R.F. Zec, E.S. Landreth, S.K. Vicari, E. Feldman, J. Belman, A. Andrise, et al. (1992) Alzheimer disease assessment scale: Useful for both early detection and staging of dementia of the Alzheimer type. Alzheimer Dis Assoc Disord 6(2), 89-102.
244. W.G. Rosen, R.C. Mohs and K.L. Davis (1984) A new rating scale for Alzheimer's disease. Am J Psychiatr 141(11), 1356-1364.
245. D. Braida, E. Paladini, P. Griffini, M. Lamperti, A. Maggi and M. Sala (1996 Apr 29) An inverted U-shaped curve for heptylphysostigmine on radial maze performance in rats: Comparison with other cholinesterase inhibitors. Eur J Pharm 302(1–3), 13-20.
246. T. Wang and X.C. Tang (1998 May 22) Reversal of scopolamine-induced deficits in radial maze performance by (-)-huperzine A: Comparison with E2020 and tacrine. Eur J Pharm 349(2–3), 137-142.
247. D.H. Cheng and X.C. Tang (1998) Comparative studies of huperzine A, E2020, and tacrine on behavior and cholinesterase activities. Pharmacol Biochem Behav 60(2), 377-386.
248. D.H. Cheng, H. Ren and X.C. Tang (1996 Dec 20) Huperzine A, a novel promising acetylcholinesterase inhibitor. Neuroreport 8(1), 97-101.
249. G. Poorheidari, K.J. Stanhope and J.A. Pratt (1998) Effects of the potassium channel blockers, apamin and 4-aminopyridine, on scopolamine-induced deficits in the delayed matching to position task in rats: A comparison with the cholinesterase inhibitor E2020. Psychopharmacology (Berl) 135(3), 242-255.
250. G.A. Higgins, M. Enderlin, R. Fimbel, M. Haman, A.J. Grottick, M. Soriano, et al. (2002) Donepezil reverses a mnemonic deficit produced by scopolamine but not by perforant path lesion or transient cerebral ischaemia. Eur J Neurosci 15(11), 1827-1840.
251. G.R. Dawson and S.D. Iversen (1993 Nov 30) The effects of novel cholinesterase inhibitors and selective muscarinic receptor agonists in tests of reference and working memory. Behav Brain Res 57(2), 143-153.
252. C.A. Barnes, J. Meltzer, F. Houston, G. Orr, K. McGann and G.L. Wenk (2000) Chronic treatment of old rats with donepezil or galantamine: Effects on memory, hippocampal plasticity and nicotinic receptors. Neuroscience 99(1), 17-23.
253. D.C. Rogers and J.J. Hagan (2001) 5-HT6 receptor antagonists enhance retention of a water maze task in the rat. Psychopharmacology (Berl) 158(2), 114-119.
254. H. Ogura, T. Kosasa, Y. Kuriya and Y. Yamanishi (2000) Donepezil, a centrally acting acetylcholinesterase inhibitor, alleviates learning deficits in hypocholinergic models in rats. Meth Find Exp Clin Pharmacol 22(2), 89-95.
255. G.J. Carey, W. Billard, H. Binch III., M. Cohen-Williams, G. Crosby, M. Grzelak, et al. (2001 Nov 16) SCH 57790, a selective muscarinic M(2) receptor antagonist, releases acetylcholine and produces cognitive enhancement in laboratory animals. Eur J Pharm 431(2), 189-200.
256. M.D. Lindner, J.B. Hogan, D.B. Hodges Jr., A.F. Orie, P. Chen, J.A. Corsa, et al. (2006) Donepezil primarily attenuates scopolamine-induced deficits in psychomotor function, with moderate effects on simple conditioning and attention, and small effects on working memory and spatial mapping. Psychopharmacology (Berl) 188(4), 629-640.
257. J.J. Buccafusco and A.V. Terry (2004) Donepezil-induced improvement in delayed matching accuracy by young and old rhesus monkeys. J Mol Neurosci 24(1), 85-91.
258. R.T. Bartus, R.L. Dean and B. Beer (1983) An evaluation of drugs for improving memory in aged monkeys: Implications for clinical trials in humans. Psychopharmacol Bull 19(2), 168-184.
259. J.J. Buccafusco and W.J. Jackson (1991) Beneficial effects of nicotine administered prior to a delayed matching-to-sample task in young and aged monkeys. Neurobiol Aging 12(3), 233-238.
260. R.T. Bartus (2000) On neurodegenerative diseases, models, and treatment strategies: Lessons learned and lessons forgotten a generation following the cholinergic hypothesis. Exp Neurol 163(2), 495-529.
261. R.L. Gould, R.G. Brown, A.M. Owen, E.T. Bullmore, S.C. Williams and R.J. Howard (2005) Functional neuroanatomy of successful paired associate learning in Alzheimer's disease. Am J Psychiatr 162(11), 2049-2060.
262. P.N. Tariot, M.R. Farlow, G.T. Grossberg, S.M. Graham, S. McDonald and I. Gergel (2004 Jan 21) Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial. JAMA 291(3), 317-324.
263. A.V. Terry Jr., J.J. Buccafusco and G.D. Bartoszyk (2005) Selective serotonin 5-HT2A receptor antagonist EMD 281014 improves delayed matching performance in young and aged rhesus monkeys. Psychopharmacology (Berl) 179(4), 725-732.
264. M.G. Paule, P.J. Bushnell, J.P. Maurissen, G.R. Wenger, J.J. Buccafusco, J.J. Chelonis, et al. (1998) Symposium overview: the use of delayed matching-to-sample procedures in studies of short-term memory in animals and humans. Neurotoxicol Teratol 20(5), 493-502.
265. A.V. Terry Jr., W.J. Jackson and J.J. Buccafusco (1993) Effects of concomitant cholinergic and adrenergic stimulation on learning and memory performance by young and aged monkeys. Cereb Cortex 3(4), 304-312.
266. J.J. Buccafusco, W.J. Jackson, J.D. Stone and A.V. Terry (2003) Sex dimorphisms in the cognitive-enhancing action of the Alzheimer's drug donepezil in aged Rhesus monkeys. Neuropharmacology 44(3), 381-389.
267. M.A. Taffe, M.R. Weed, T. Gutierrez, S.A. Davis and L.H. Gold (2004 Mar 2) Modeling a task that is sensitive to dementia of the Alzheimer's type: Individual differences in acquisition of a visuo-spatial paired-associate learning task in rhesus monkeys. Behav Brain Res 149(2), 123-133.
268. M.R. Weed, M.A. Taffe, I. Polis, A.C. Roberts, T.W. Robbins, G.F. Koob, et al. (1999 Oct 25) Performance norms for a rhesus monkey neuropsychological testing battery: Acquisition and long-term performance. Brain Res Cogn Brain Res 8(3), 185-201.
269. J.J. Buccafusco, A.V. Terry Jr. and P.B. Murdoch (2002) A computer-assisted cognitive test battery for aged monkeys. J Mol Neurosci 19 179-185.
270. R.G.M. Morris (1981) Spatial localization does not require the presence of local cues. Learn Motiv 12 239-260.
271. L.E. Jarrard (1978) Selective hippocampal lesions: Differential effects on performance by rats of a spatial task with preoperative versus postoperative training. J Comp Physiol Psychol 92(6), 1119-1127.
272. D.S. Olton and B.C. Papas (1979) Spatial memory and hippocampal function. Neuropsychologia 17 669-682.
273. S.B. Dunnett, J.L. Evenden and S.D. Iversen (1988) Delay-dependent short-term memory deficits in aged rats. Psychopharmacology 96 174-180.
274. S.B. Dunnett (1990) Role of prefrontal cortex and striatal output systems in short-term memory deficits associated with ageing, basal forebrain lesions, and cholinergic-rich grafts. Can J Psychol 44(2), 210-232.
275. M. Carli, T.W. Robbins, J.L. Evenden and B.J. Everitt (1983) Effects of lesions to ascending noradrenergic neurones on performance of a 5-choice serial reaction task in rats; implications for theories of dorsal noradrenergic bundle function based on selective attention and arousal. Behav Brain Res 9(3), 361-380.
276. T.W. Robbins (2002) The 5-choice serial reaction time task: behavioural pharmacology and functional neurochemistry. Psychopharmacology (Berl) 163(3–4), 362-380.
277. Goldman-Rakic, P.S. (1996 Oct 29). The prefrontal landscape: implications of functional architecture for understanding human mentation and the central executive, Philos Trans R Soc Lond B Biol Sci. 351(1346): 1445–1453.
278. P.J. Fray, T.W. Robbins and B.J. Sahakian (1996) Neuropsychiatric applications of CANTAB. Int J Geriatr Psychiatr 11 329-336.
279. B.J. Sahakian (1990) Computerized assessment of neuropsychological function in Alzheimer's disease and Parkinson's disease. Int J Geriatr Psychiatr 5 211-213.
280. T.W. Robbins, M. James, A.M. Owen, B.J. Sahakian, L. McInnes and P. Rabbitt (1994) Cambridge Neuropsychological Test Automated Battery (CANTAB): A factor analytic study of a large sample of normal elderly volunteers. Dementia 5(5), 266-281.
281. T.W. Robbins, M. James, A.M. Owen, B.J. Sahakian, A.D. Lawrence, L. McInnes, et al. (1998) A study of performance on tests from the CANTAB battery sensitive to frontal lobe dysfunction in a large sample of normal volunteers: Implications for theories of executive functioning and cognitive aging. Cambridge Neuropsychological Test Automated Battery. J Int Neuropsychol Soc 4(5), 474-490.
282. C.R. De Luca, S.J. Wood, V. Anderson, J.A. Buchanan, T.M. Proffitt, K. Mahony, et al. (2003) Normative data from the CANTAB. I: Development of executive function over the lifespan. J Clin Exp Neuropsychol 25(2), 242-254.
283. R.C. Martin, S.M. Sawrie, F.G. Gilliam, C.A. Palmer, E. Faught, R.B. Morawetz, et al. (2000) Wisconsin Card Sorting performance in patients with temporal lobe epilepsy: Clinical and neuroanatomical correlates. Epilepsia 41(12), 1626-1632.
284. A.M. Owen, A.C. Roberts, C.E. Polkey, B.J. Sahakian and T.W. Robbins (1991) Extra-dimensional versus intra-dimensional set shifting performance following frontal lobe excisions, temporal lobe excisions or amygdalo-hippocampectomy in man. Neuropsychologia 29(10), 993-1006.
285. B.J. Sahakian, R. Elliott, N. Low, M. Mehta, R.T. Clark and A.L. Pozniak (1995) Neuropsychological deficits in tests of executive function in asymptomatic and symptomatic HIV-1 seropositive men. Psychol Med 25(6), 1233-1246.
286. M.R. Weed, L.H. Gold, I. Polis, G.F. Koob, H.S. Fox and M.A. Taffe (2004) Impaired performance on a rhesus monkey neuropsychological testing battery following simian immunodeficiency virus infection. AIDS Res Hum Retrovir 20(1), 77-89.
287. S.C. Baker, R.D. Rogers, A.M. Owen, C.D. Frith, R.J. Dolan, R.S. Frackowiak, et al. (1996) Neural systems engaged by planning: A PET study of the Tower of London task. Neuropsychologia 34(6), 515-526.
288. R.L. Gould, R.G. Brown, A.M. Owen, D.H. ffytche and R.J. Howard (2003) fMRI BOLD response to increasing task difficulty during successful paired associates learning. Neuroimage 20(2), 1006-1019.
289. C.E. Stern, A.M. Owen, I. Tracey, R.B. Look, B.R. Rosen and M. Petrides (2000) Activity in ventrolateral and mid-dorsolateral prefrontal cortex during nonspatial visual working memory processing: Evidence from functional magnetic resonance imaging. Neuroimage 11(5 Pt 1), 392-399.
290. S.J. Reeves, P.M. Grasby, R.J. Howard, R.A. Bantick, M.C. Asselin and M.A. Mehta (2005 Oct 15) A positron emission tomography (PET) investigation of the role of striatal dopamine (D2) receptor availability in spatial cognition. Neuroimage 28(1), 216-226.
291. P.C. Pearce, H.S. Crofts, N.G. Muggleton and E.A. Scott (1998 Feb 15) Concurrent monitoring of EEG and performance in the common marmoset: A methodological approach. Physiol Behav 63(4), 591-599.
292. S. Spinelli, L. Pennanen, A.C. Dettling, J. Feldon, G.A. Higgins and C.R. Pryce (2004) Performance of the marmoset monkey on computerized tasks of attention and working memory. Brain Res Cogn Brain Res 19(2), 123-137.
293. S. Spinelli, T. Ballard, S. Gatti-McArthur, G.J. Richards, M. Kapps, T. Woltering, et al. (2005) Effects of the mGluR2/3 agonist LY354740 on computerized tasks of attention and working memory in marmoset monkeys. Psychopharmacology (Berl) 179(1), 292-302.
294. K.S. Fowler, M.M. Saling, E.L. Conway, J.M. Semple and W.J. Louis (1997) Computerized neuropsychological tests in the early detection of dementia: Prospective findings. J Int Neuropsychol Soc 3(2), 139-146.
295. K.S. Fowler, M.M. Saling, E.L. Conway, J.M. Semple and W.J. Louis (2002) Paired associate performance in the early detection of DAT. J Int Neuropsychol Soc 8(1), 58-71.
296. R.L. Gould, B. Arroyo, R.G. Brown, A.M. Owen, E.T. Bullmore and R.J. Howard (2006 Sep 26) Brain mechanisms of successful compensation during learning in Alzheimer disease. Neurology 67(6), 1011-1017.
297. N.H. Greig, K. Sambamurti, Q.S. Yu, A. Brossi, G.B. Bruinsma and D.K. Lahiri (2005) An overview of phenserine tartrate, a novel acetylcholinesterase inhibitor for the treatment of Alzheimer's disease. Curr Alzheimer Res 2(3), 281-290.
298. K.T. Shaw, T. Utsuki, J. Rogers, Q.S. Yu, K. Sambamurti, A. Brossi, et al. (2001 Jun 19) Phenserine regulates translation of beta-amyloid precursor protein mRNA by a putative interleukin-1 responsive element, a target for drug development. Proc Natl Acad Sci USA 98(13), 7605-7610.
299. Kirby, L.C., Baumel, B., Eisner, L.S., Safirstien, B.E., and Burford, R.G. (2002). The efficacy of phenserine tartrate following twelve (12) weeks of treatment in Alzheimer disease patients, International Symposium on Advances in Alzheimer Therapy, Geneva, Switzerland.
300. R.E. Hampson and S.A. Deadwyler (1994) Hippocampal representations of DMS/DNMS in the rat. Behav Brain Sci 17 480-482.
301. R.E. Hampson and S.A. Deadwyler (1996) Ensemble codes involving hippocampal neurons are at risk during delayed performance tests. Proc Natl Acad Sci USA 93 13487-13493.
302. S.A. Deadwyler and R.E. Hampson (1997) The significance of neural ensemble codes during behavior and cognition. W.M. Cowan, E.M. Shooter, C.F. Stevens, R.F. Thompson (Eds) Annual Review of Neuroscience Vol. 20 Palo Alto, CA: Annual Reviews, Inc. 217-244.
303. R.E. Hampson, J.D. Simeral and S.A. Deadwyler (1999) Distribution of spatial and nonspatial information in dorsal hippocampus. Nature 402 610-614.
304. R.E. Hampson, J.D. Simeral and S.A. Deadwyler (2001) What ensemble recordings reveal about functional hippocampal cell encoding. Prog Brain Res 130 345-357.
305. R.E. Hampson and S.A. Deadwyler (2003) Temporal firing characteristics and the strategic role of subicular neurons in short-term memory. Hippocampus 13 529-541.
306. R.E. Hampson, G. Rogers, G. Lynch and S.A. Deadwyler (1998) Facilitative effects of the ampakine CX516 on short-term memory in rats: Enhancement of delayed-nonmatch-to-sample performance. J Neurosci 18 2740-2747.
307. R.E. Hampson, G. Rogers, G. Lynch and S.A. Deadwyler (1998) Facilitative effects of the ampakine CX516 on short-term memory in rats: Correlations with hippocampal ensemble activity. J Neurosci 18 2748-2763.
308. V. Suppiramaniam, B.A. Bahr, S. Sinnarajah, K. Owens, G. Rogers, S. Yilma, et al. (2001) Member of the Ampakine class of memory enhancers prolongs the single channel open time of reconstituted AMPA receptors. Synapse 40 154-158.
309. A.C. Arai, M. Kessler, G. Rogers and G. Lynch (2000) Effects of the potent ampakine CX614 on hippocampal and recombinant AMPA receptors: Interactions with cyclothiazide and GYKI 52466. Mol Pharmacol 58 802-813.
310. A.C. Arai, Y.F. Xia, G. Rogers, G. Lynch and M. Kessler (2002) Benzamide-type AMPA receptor modulators form two subfamilies with distinct modes of action. J Pharmacol Exp Ther 303 1075-1085.
311. K. Fukuda, J.A. Stern, T.B. Brown and M.B. Russo (2005) Cognition, blinks, eye-movements, and pupillary movements during performance of a running memory task. Aviat Space Environ Med 76 C75-cC85.
312. P.W. Van Gerven, F. Paas, J.J. Van Merrienboer and H.G. Schmidt (2004) Memory load and the cognitive pupillary response in aging. Psychophysiology 41 167-174.
313. E. Granholm and S.R. Steinhauer (2004) Pupillometric measures of cognitive and emotional processes. Int J Psychophysiol 52 1-6.
314. E. Granholm, R.F. Asarnow, A.J. Sarkin and K.L. Dykes (1996) Pupillary responses index cognitive resource limitations. Psychophysiology 33 457-461.
315. J. Beatty and B.L. Wagoner (1978 Mar 17) Pupillometric signs of brain activation vary with level of cognitive processing. Science 199 1216-1218.
316. S.P. Marshall (2007) Identifying cognitive state from eye metrics. Aviat Space Environ Med 78 B165-bB175.
317. M. Delfino, R. Kalisch, M. Czisch, C. Larramendy, J. Ricatti, I.R. Taravini, et al. (2007 Feb 7) Mapping the effects of three dopamine agonists with different dyskinetogenic potential and receptor selectivity using pharmacological functional magnetic resonance imaging. Neuropsychopharmacology 32(9), 1911-1921.
318. S.M. Smirnakis, A.A. Brewer, M.C. Schmid, A.S. Tolias, A. Schuz, M. Augath, et al. (2005 May 19) Lack of long-term cortical reorganization after macaque retinal lesions. Nature 435(7040), 300-307.
319. F. Zhao, P. Wang and S.G. Kim (2004) Cortical depth-dependent gradient-echo and spin-echo BOLD fMRI at 9.4T. Magn Reson Med 51(3), 518-524.
320. J.F. Poduslo, T.M. Wengenack, G.L. Curran, T. Wisniewski, E.M. Sigurdsson, S.I. Macura, et al. (2002) Molecular targeting of Alzheimer's amyloid plaques for contrast-enhanced magnetic resonance imaging. Neurobiol Dis 11(2), 315-329.
321. G.B. Fox, S. McGaraughty and Y. Luo (2006) Pharmacological and functional magnetic resonance imaging techniques in CNS drug discovery. Expet Opin Drug Discov 1 211-224.
322. K. Elrod, J.J. Buccafusco and W.J. Jackson (1988) Nicotine enhances delayed matching-to-sample performance by primates. Life Sci 43 277-287.
323. E.T. Rolls, P.M. Cahusac, J.D. Feigenbaum and Y. Miyashita (1993) Responses of single neurons in the hippocampus of the macaque related to recognition memory. Exp Brain Res 93(2), 299-306.
324. M.J. Tovee, E.T. Rolls, A. Treves and R.P. Bellis (1993) Information encoding and the responses of single neurons in the primate temporal visual cortex. J Neurophysiol 70 640-654.
325. R.G.M. Morris, J.L. Evenden, B.J. Sahakian and T.W. Robbins (1987) Computer-aided assessment of dementia: Comparative studies of neuropsychological deficits in Alzheimer-type dementia and Parkinson's disease. S.M. Stahl, S.D. Iversen, E.C. Goodman (Eds) Cognitive Neuroschemistry Oxford: Oxford University Press 21-36.
326. S.J. Pittler and W. Baehr (1991 Oct 1) Identification of a nonsense mutation in the rod photoreceptor cGMP phosphodiesterase beta-subunit gene of the rd mouse. Proc Natl Acad Sci USA 88(19), 8322-8326.
327. M.F. Garcia, M.N. Gordon, M. Hutton, J. Lewis, E. McGowan, C.A. Dickey, et al. (2004 Jan 19) The retinal degeneration (rd) gene seriously impairs spatial cognitive performance in normal and Alzheimer's transgenic mice. Neuroreport 15(1), 73-77.
328. Hsiao, K., Borchelt, D.R. Sisodia, S. inventors, Johns Hopkins University RotUoM, assignee, (1999). Transgenic mice expressing APP-Swedish mutation develop progressive neurologic disease. U.S. Patent Office patent US 5,877,399.
329. J.C. Harris (1989) Experimental animal modeling of depression and anxiety. Psychiatr Clin North Am 12(4), 815-836.
330. M.D. Lindner, M.A. Plone, T. Schallert and D.F. Emerich (1997) Blind rats are not profoundly impaired in the reference memory Morris water maze and cannot be clearly discriminated from rats with cognitive deficits in the cued platform task. Brain Res Cogn Brain Res 5(4), 329-333.
331. M.D. Lindner and V.K. Gribkoff (1991) Relationship between performance in the Morris water task, visual acuity, and thermoregulatory function in aged F-344 rats. Behav Brain Res 45 45-55.
332. R. Rosenthal (1966) Experimenter Effects in Behavioral Research. NY: Appleton Century Crofts (Division of Meredith Publishing Co.)
333. M.D. Lindner (2007) Clinical attrition due to biased preclinical assessments of potential efficacy. Pharmacol Ther 115(1), 148-175.
334. P. Cuatrecasas (2006) Drug discovery in jeopardy. J Clin Invest 116(11), 2837-2842.
335. P.N. Tariot and H.J. Federoff (2003) Current treatment for Alzheimer disease and future prospects. Alzheimer Dis Assoc Disord 17(Suppl 4), S105-sS113.
336. M. Packer, J.R. Carver, R.J. Rodeheffer, R.J. Ivanhoe, R. DiBianco, S.M. Zeldis, et al. (1991 Nov 21) Effect of oral milrinone on mortality in severe chronic heart failure, The PROMISE Study Research Group. N Engl J Med 325(21), 1468-1475.
337. The Cardiac Arrhythmia Suppression Trial (CAST) Investigators (1989 Aug 10) Preliminary report: Effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. N Engl J Med 321(6), 406-412.
338. The Cardiac Arrhythmia Suppression Trial II Investigators (1992 Jul 23) Effect of the antiarrhythmic agent moricizine on survival after myocardial infarction. N Engl J Med 327(4), 227-233.
339. The Xamoterol in Severe Heart Failure Study Group (1990 Jul 7) Xamoterol in severe heart failure. Lancet 336(8706), 1-6.
340. D.S. Echt, P.R. Liebson, L.B. Mitchell, R.W. Peters, D. Obias-Manno, A.H. Barker, et al. (1991 Mar 21) Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial. N Engl J Med 324(12), 781-788.
341. S.E. Coplen, E.M. Antman, J.A. Berlin, P. Hewitt and T.C. Chalmers (1990) Efficacy and safety of quinidine therapy for maintenance of sinus rhythm after cardioversion. A meta-analysis of randomized control trials. Circulation 82(4), 1106-1116.
342. L.K. Hine, N. Laird, P. Hewitt and T.C. Chalmers (1989) Meta-analytic evidence against prophylactic use of lidocaine in acute myocardial infarction. Arch Intern Med 149(12), 2694-2698.
343. D.J. Gordon (1995) Cholesterol lowering and total mortality. B.M. Rifkind (Eds) Lowering Cholesterol in High-Risk Individuals and Populations New York: Marcel Dekker, Inc. 33-48.
344. Advanced Colorectal Cancer Meta-Analysis Project (1992) Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: Evidence in terms of response rate. J Clin Oncol 10(6), 896-903.
345. T.R. Fleming (1994 Jul 15) Surrogate markers in AIDS and cancer trials. Stat Med 13(13–14), 1423-1435.
346. T.R. Fleming (2005) Surrogate endpoints and FDA's accelerated approval process. Health Aff (Millwood) 24(1), 67-78.
347. R.E. Chaisson, C.A. Benson, M.P. Dube, L.B. Heifets, J.A. Korvick, S. Elkin, et al. (1994 Dec 15) Clarithromycin therapy for bacteremic Mycobacterium avium complex disease. A randomized, double-blind, dose-ranging study in patients with AIDS. AIDS Clinical Trials Group Protocol 157 Study Team. Ann Intern Med 121(12), 905-911.
348. S.E. Nissen and K. Wolski (2007 Jun 14) Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 356(24), 2457-2471.
349. B.L. Riggs, S.F. Hodgson, W.M. O'Fallon, E.Y. Chao, H.W. Wahner, J.M. Muhs, et al. (1990 Mar 22) Effect of fluoride treatment on the fracture rate in postmenopausal women with osteoporosis. N Engl J Med 322(12), 802-809.
350. The International Chronic Granulomatous Disease Cooperative Study Group (1991 Feb 21) A controlled trial of interferon gamma to prevent infection in chronic granulomatous disease. N Engl J Med 324(8), 509-516.
351. R.D. Smith, M.K. Kistler, M. Cohen-Williams and V.L. Coffin (1996 Jan 22) Cholinergic improvement of a naturally-occurring memory deficit in the young rat. Brain Res 707(1), 13-21.
352. K. Tokita, S. Yamazaki, M. Yamazaki, N. Matsuoka and S. Mutoh (2002) Combination of a novel antidementia drug FK960 with donepezil synergistically improves memory deficits in rats. Pharmacol Biochem Behav 73(3), 511-519.
353. Y. Yamaguchi, M. Higashi, T. Matsuno and S. Kawashima (2001) Ameliorative effects of azaindolizinone derivative ZSET845 on scopolamine-induced deficits in passive avoidance and radial-arm maze learning in the rat. Jpn J Pharmacol 87(3), 240-244.
354. T. Sato, K. Tanaka, Y. Ohnishi, M. Irifune and T. Nishikawa (2003) Effect of donepezil on group II mGlu receptor agonist- or antagonist-induced amnesia on passive avoidance in mice. Neural Plast 10(4), 319-325.
355. M. Suzuki, T. Yamaguchi, Y. Ozawa, M. Ohyama and M. Yamamoto (1995) Effects of (-)-S-2,8-dimethyl-3-methylene-1-oxa-8-azaspiro[4,5]decane l-tartrate monohydrate (YM796), a novel muscarinic agonist, on disturbance of passive avoidance learning behavior in drug-treated and senescence-accelerated mice. J Pharmacol Exp Ther 275(2), 728-736.
356. H. Dong, C.A. Csernansky, M.V. Martin, A. Bertchume, D. Vallera and J.G. Csernansky (2005) Acetylcholinesterase inhibitors ameliorate behavioral deficits in the Tg2576 mouse model of Alzheimer's disease. Psychopharmacology (Berl) 181(1), 145-152.
357. L. Spowart-Manning and F.J. van der Staay (2004 May 5) The T-maze continuous alternation task for assessing the effects of putative cognition enhancers in the mouse. Behav Brain Res 151(1–2), 37-46.
358. B. Bontempi, K.T. Whelan, V.B. Risbrough, G.K. Lloyd and F. Menzaghi (2003) Cognitive enhancing properties and tolerability of cholinergic agents in mice: A comparative study of nicotine, donepezil, and SIB-1553A, a subtype-selective ligand for nicotinic acetylcholine receptors. Neuropsychopharmacology 28(7), 1235-1246.
359. D.L. Kirkby, D.N. Jones, J.C. Barnes and G.A. Higgins (1996) Effects of anticholinesterase drugs tacrine and E2020, the 5-HT(3) antagonist ondansetron, and the H(3) antagonist thioperamide, in models of cognition and cholinergic function. Behav Pharmacol 7(6), 513-525.
360. C. Balducci, M. Nurra, A. Pietropoli, R. Samanin and M. Carli (2003) Reversal of visual attention dysfunction after AMPA lesions of the nucleus basalis magnocellularis (NBM) by the cholinesterase inhibitor donepezil and by a 5-HT1A receptor antagonist WAY 100635. Psychopharmacology (Berl) 167(1), 28-36.
361. V.N. Luine, G. Mohan, Z. Tu and S.M. Efange (2002) Chromaproline and Chromaperidine, nicotine agonists, and Donepezil, cholinesterase inhibitor, enhance performance of memory tasks in ovariectomized rats. Pharmacol Biochem Behav 74(1), 213-220.
362. J. Prickaerts, A. Sik, F.J. van der Staay, J. de Vente and A. Blokland (2005) Dissociable effects of acetylcholinesterase inhibitors and phosphodiesterase type 5 inhibitors on object recognition memory: Acquisition versus consolidation. Psychopharmacology (Berl) 177(4), 381-390.
363. F.J. van der Staay and P.C. Bouger (2005 Jan 6) Effects of the cholinesterase inhibitors donepezil and metrifonate on scopolamine-induced impairments in the spatial cone field orientation task in rats. Behav Brain Res 156(1), 1-10.
364. F.J. van der Staay, V.C. Hinz and B.H. Schmidt (1996) Effects of metrifonate, its transformation product dichlorvos, and other organophosphorus and reference cholinesterase inhibitors on Morris water escape behavior in young-adult rats. J Pharmacol Exp Ther 278(2), 697-708.
365. H. Hodges, P. Sowinski, J.J. Turner and A. Fletcher (1996) Comparison of the effects of the 5-HT3 receptor antagonists WAY-100579 and ondansetron on spatial learning in the water maze in rats with excitotoxic lesions of the forebrain cholinergic projection system. Psychopharmacology (Berl) 125(2), 146-161.
366. Z. Chen, A.J. Xu, R. Li and E.Q. Wei (2002) Reversal of scopolamine-induced spatial memory deficits in rats by TAK-1471. Acta Pharmacol Sin 23(4), 355-360.
367. A.J. Xu, Z. Chen, K. Yanai, Y.W. Huang and E.Q. Wei (2002 Oct 4) Effect of 3-[1-(phenylmethyl)-4-piperidinyl]-1-(2,3,4,5-tetrahydro-1H-1-benzazepin-8 -yl)-1-propanone fumarate, a novel acetylcholinesterase inhibitor, on spatial cognitive impairment induced by chronic cerebral hypoperfusion in rats. Neurosci Lett 331(1), 33-36.
368. D.D. Van, D. Abramowski, M. Staufenbiel and P.P. De Deyn (2005) Symptomatic effect of donepezil, rivastigmine, galantamine and memantine on cognitive deficits in the APP23 model. Psychopharmacology (Berl) 180(1), 177-190.
369. Y. Abe, A. Aoyagi, T. Hara, K. Abe, R. Yamazaki, Y. Kumagae, et al. (2003) Pharmacological characterization of RS-1259, an orally active dual inhibitor of acetylcholinesterase and serotonin transporter, in rodents: Possible treatment of Alzheimer's disease. J Pharmacol Sci 93(1), 95-105.
370. J. Cohen (1988) Statistical Power Analysis for the Behavioral Sciences. 2 ed Hillsdale, New Jersey: Lawrence Erlbaum Associates, Inc.